Home
Explore
Journal Club
Trending
More
synapse
⌘+K
Language
English
English
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma | Synapse
March 3, 2026
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
SS
Sergi V. Salsench
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
GF
Gerardo Ferrer
Universidad de la República de Uruguay
AO
Almudena Garcia Ortiz
See all
Key Points
PVR (CD155) epigenetic status directly influences immunotherapy response.
The study highlights a potential average survival difference of 12 months based on epigenetic modifications.
Analysis reveals varying PVR (CD155) expression levels in multiple myeloma patients undergoing treatment.
Understanding PVR (CD155) epigenetics may lead to improved immunotherapy strategies and patient outcomes.
Mark Helpful
Mark Helpful
Save
Bookmark
Relay
Relay
Mark Helpful
Mark Helpful
Save
Bookmark
Relay
Relay
Cite This Study
Copy
Salsench et al. (Tue,) studied this question.
synapsesocial.com/papers/69a75e5ec6e9836116a28db9